Business Context and Reporting Period
This Form 8-K Current Report was filed by Aziyo Biologics, Inc. (not Elutia Inc.) on December 8, 2021, covering events occurring on December 5, 2021. The registrant is a Delaware corporation with its principal executive offices in Silver Spring, Maryland, and its Class A Common Stock trades on The Nasdaq Global Market under the symbol "AZYO". The company is classified as an emerging growth company.
Key Financial Metrics
The filing details a private placement equity offering rather than operational financial results. Key transaction metrics include:
- Aggregate Gross Proceeds: Approximately $14.0 million (before offering expenses).
- Offering Price: $4.24 per share.
- Securities Issued:
- 2,122,637 shares of Class A Common Stock.
- 1,179,244 shares of Class B Common Stock.
- Closing Date: December 8, 2021.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the entry into a Securities Purchase Agreement and a Registration Rights Agreement. The company raised capital through the sale of Class A and Class B common stock to certain investors. The Class B shares are convertible into Class A shares. This transaction represents a significant increase in the company's equity capital base.
Guidance, Outlook, and Risks
Management Commentary and Agreements:
- The company agreed to file a registration statement with the SEC within 45 days of the closing (by mid-January 2022) to register the resale of the Class A Shares and the Conversion Shares.
- The company committed to using commercially reasonable efforts to have the registration statement declared effective within 75 days of closing (or 105 days if reviewed by the SEC).
- The company agreed to indemnify investors against certain liabilities and pay fees and expenses related to the registration, excluding legal fees of selling holders and underwriting discounts.
Risks and Contingencies:
- The offering was exempt from registration under Section 4(a)(2) of the Securities Act and Regulation D.
- Investors have not acquired securities for distribution in violation of the Securities Act of 1933.
- Representations and warranties in the purchase agreement are qualified and should not be relied upon as general factual disclosures.
Investor Verification Checklist
- Verify the final net proceeds after deducting offering expenses, as the $14.0 million figure is gross.
- Confirm the terms of the Class B Common Stock conversion into Class A Common Stock.
- Review the filed Registration Rights Agreement (Exhibit 10.2) for specific timelines and obligations regarding the resale registration.
- Check subsequent filings to confirm the SEC declared the registration statement effective within the agreed-upon timeframe.
- Assess the impact of the new share issuance on existing shareholder dilution.